JAPAN HEALTHCARE VENTURE SUMMIT

AMED Seeds Acceleration Pitch

Seeds recommended by AMED and MEDISO will be introduced through pitch presentations. Each project leader will deliver a supporting speech for their seeds. Moderators and AMED-certified VCs will provide advice and comments aimed at commercialization and business development.

Date October 9, 2024 (Wed) 13:30 -

Venue Pacifico Yokohama JHVS Stage

Program	
13:30	**Opening Remarks** **Yoshinao MISHIMA,** President, Japan Agency for Medical Research and Development **Hideshi SENBA,** Deputy Director-General, National Health Policy Secretariat, Cabinet Office **Hirokazu SHIMODA,** Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry **Daisuke YOSHIZUMI,** Investment Banking, Head of Japan healthcare, J.P.Morgan
13:50 14:35 15:10	**Seed Pitches [Session 1] & Question and Answer Feedback** **Seed Pitches [Session 2] & Question and Answer Feedback** **Seed Pitches [Session 3] & Question and Answer Feedback** **Presenters:** Refer to the introduction section **Moderators:** **Shunichi TAKAHASHI,** PhD, President & Chief Operating Officer, LINK-J **Taro INABA,** Managing Partner, Remiges ventures **Commentators:** **Yoshinao MISHIMA,** President of Japan Agency for Medical Research and Development (AMED) **Takashi UCHIDA,** Chief Manager, Department of Intellectual Property and Technology Transfer, Japan Agency for Medical Research and Development (AMED) **Hirokazu SHIMODA,** Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy, Trade and Industry (METI) AMED-Certified Venture Capitalists
15:50	**General Remarks** **Naoko OKAMURA,** Executive Advisor to the President, Senior Director, Japan Agency for Medical Research and Development
16:00	**Networking** AMED-Certified VCs and Presenters will participate

Japan Agency for Medical Research and Development

MEDISO Medical Innovation Support Office

Organized by: AMED × MEDISO

Introduction of Pitch Presenters

Session 1

Hiroyuki Seimiya, Japanese Foundation for Cancer Research

Tankyrase inhibitor, RK-582, an innovative new drug targeting unmet needs in colorectal cancer

Colorectal cancer (CRC) causes over 900,000 deaths annually worldwide. Targeting the Wnt pathway, a major driver of CRC, has been considered challenging. RK-582 inhibits the Wnt pathway and suppresses CRC growth. Predictive biomarkers for the efficacy have also been identified, and a phase I clinical trial will begin soon.

Takafumi Nakamura, Tottori University

Next-generation oncolytic virus for innovative cancer treatment

Virotherapy is novel cancer treatment with oncolytic viruses which induce antitumor immunity following direct viral oncolysis. However, the clinical benefits of oncolytic virotherapy are limited. Thus, we have developed iOV system which customizes oncolytic virus to overcome virotherapy-resistant tumors.

Ken Ohmine, Jichi Medical University

Development of Erythropoietin-inducible Selective Regulatory Genes for CAR-T Therapy

SRG, a unique gene therapy technology, is designed to enhance the proliferation and persistence of CAR-T cells in the patient's body by administering erythropoietin, leading to a superior therapeutic effect. This novel approach can also be applied in various T-cell-based therapeutic strategies, boosting their potency.

Session 2

Hiroshi Hamamoto, Yamagata University

Development of Lysocin E, a therapeutic agent for refractory MRSA infections with a novel mechanism of action

Lysocin E is an antibiotic with a novel structure and mechanism of action. It is in preclinical development involving GLP-compliant safety studies, for the treatment of MRSA infections that are resistant to existing antibacterial agents. Since it has extraordinary short-time and potent bactericidal action.

Yuji Suzuki, Ohsugi & Naka's Start-up with Spirit of Innovation Corporation

Development of innovative antibody-drug conjugate targeting cancer and stroma against pancreatic cancer

GPC1-ADC, an antibody-drug conjugate targeting Glypican-1, represents an innovative approach to cancer therapy. It offers dual antitumor effects: directly on cancer cells and indirectly through cancer-associated fibroblasts within the tumor stroma. This dual action holds promise for treating pancreatic cancer, known for its dense stromal environment.

Hirotsu Tatsunori, CyDing Co.

Saving Relapsed and Refractory Leukemia Patients with Cyclodextrin-Based Therapy

Approximately 25% of leukemia patients lose treatment options due to drug resistance or intolerance, leading to end-of-life suffering without available therapies. For this, we are developing a groundbreaking treatment utilizing cyclodextrin, which offer a novel mechanism of action and minimal side effects.

Yuji Otsuki, Fujita Health University / FerroptoCure Inc.

Ferroptosis inducing anti-cancer therapy

We are developing an anti-cancer drug that utilizes ferroptosis (cell death caused by oxidative stress). Inhibiting ferroptosis is gaining attention as a mechanism involved in cancer growth and treatment resistance. This drug will be applicable to a wide range of cancer types.

Session 3

Msayuki Aso, CellGenTech, Inc.

New modality by using Genetically modified human adipocyte for Regenerative Medicine to Treat Intractable Diseases

We are conducting research and development of Genetically Modified human Adipocyte medicines for the treatment of intractable diseases. 7 years of clinical research on LCAT deficiency has suggested safety and efficacy, and we are developing the platform technology for practical application to hemophilia A.

Akifumi Morinaka, Rege Nephro Co.

Cell therapy for CKD using iPSC-Derived Nephron Progenitor Cells

Nephron progenitor cells (NPCs) are cells that give rise to nephrons. Rege Nephro is developing cell therapy implanting iNPCs (NPCs induced from allogeneic human iPSCs) into the damaged kidneys, and the improvements in renal function have been confirmed in the several mouse experiments.

Yuki Yamamoto, HiLung Inc.

Drug discovery and development for respiratory diseases utilizing iPSC technology

We at HiLung are developing HL001 for idiopathic pulmonary fibrosis, a lead preclinical pipeline designated as an orphan drug from the FDA, as well as new modalities for respiratory diseases, leveraging iPSC technology.

Genjiro Miwa, PorMedTec Co., Ltd

Xeno-organ transplantation using bioengineered pig donors toward ending the kidney transplant shortage

Committed to ending the transplant shortage, we have been successfully reproducing organ donor pigs developed by eGenesis (USA) through our cloning technology. eGenesis pig achieved First in Human experiment in March 2024 We have been working with leading clinicians and regulatory authorities in Japan for clinical trial program of kidney followed by heart and liver.